

Alexion Pharmaceuticals (USA): Merger with Synageva BioPharma (USA) Changes in FTSE Indices

22 June 2015

Subject to the completion of the merger with Alexion Pharmaceuticals Inc. (USA, constituent) and Synageva BioPharma Corp. (USA, constituent), FTSE announces the following changes:

Index	Change	Effective From Start of Trading
FTSE All-World Index	Alexion Pharmaceuticals (USA, 2036070) will remain in the index with an increased shares in issue total of 224,033,763 and an unchanged investability weighting of 100%.	25 June 2015
FTSE MPF All-World Index	Alexion Pharmaceuticals will remain in the index as detailed above.	25 June 2015
FTSE Developed Index	Alexion Pharmaceuticals will remain in the index as detailed above.	25 June 2015
FTSE Global Large Cap Index	Alexion Pharmaceuticals will remain in the index as detailed above.	25 June 2015
FTSE Multinationals Index	Alexion Pharmaceuticals will remain in the index as detailed above.	25 June 2015
FTSE Global Style Index	Alexion Pharmaceuticals will remain in the index as detailed above.	25 June 2015
FTSE Global Small Cap Index	Synageva BioPharma will be deleted from the index.	25 June 2015

For further information or general enquiries please contact us at info@ftse.com or call:

Client Services in UK:	Tel: +44 (0) 20 7866 1810
Client Services in EMEA:	Tel: +44 (0) 20 7866 1810
Client Services in US:	New York: (Domestic) + 1 888 747 FTSE (3873) / (International): +1 212 314 1139
Client Services in Asia Pacific:	Hong Kong: + 852 2164 3333 Australia: (Domestic Toll-Free) + 1800 653 680 / (International) + 61 (2) 9293 2864 Japan + 81 (3) 3581 2764

Alternatively please visit our website at www.ftse.com